From: Assessment of lipophilicity of newly synthesized celecoxib analogues using reversed-phase HPLC
Compound | Log k | ||||
---|---|---|---|---|---|
60% | 65% | 70% | 75% | 80% | |
11a | 0.088 | 0.041 | − 0.206 | − 0.412 | − 0.695 |
11b | 0.317 | 0.493 | − 0.016 | − 0.235 | − 0.607 |
11c | 0.635 | 0.501 | 0.123 | − 0.036 | − 0.145 |
11d | a | 0.901 | 0.364 | 0.123 | − 0.041 |
16a | 0.130 | 0.053 | − 0.220 | − 0.424 | − 0.385 |
16b | 0.481 | 0.280 | 0.150 | − 0.233 | − 0.198 |
17a | 0.950 | 0.824 | 0.740 | − 0.12 | − 0.051 |
17b | 0.847 | 0.743 | 0.611 | − 0.221 | − 0.410 |
Celecoxib | a | 0.950 | 0.83 | 0.530 | 0.235 |